Skip to main content

Drug Interactions between amprenavir and garlic

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

garlic amprenavir

Applies to: garlic and amprenavir

GENERALLY AVOID: Coadministration with garlic supplements may decrease the plasma concentrations of saquinavir and possibly other protease inhibitors (PIs). The exact mechanism is unknown but may involve induction of CYP450 3A4 metabolism and/or P-gycloprotein transport in the intestine by certain component(s) of garlic. In nine healthy, HIV-negative volunteers, investigators from the National Institutes of Health found that pretreatment with a garlic supplement (GarliPure Maximum Allicin Formula twice daily for 3 weeks) reduced the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of saquinavir (soft gelatin capsule 1200 mg 3 times daily for 10 doses during the last 4 days of garlic supplementation) by 54% and 51%, respectively, compared to baseline when saquinavir was administered alone. The effects appear to be sustained, since saquinavir Cmax and AUC returned to just 61% and 65% of baseline, respectively, after a 10-day washout period. Whether and how dietary garlic or other formulations of garlic supplement may affect saquinavir pharmacokinetics are currently unknown. It is also uncertain if and to what extent the interaction may occur with other PIs, which are also substrates of CYP450 3A4.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, garlic supplements should preferably be avoided in patients treated with PIs, particularly if they are using saquinavir as the sole PI in their antiretroviral regimen. Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.

References

  1. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P (2000) "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids, 14, p. 1333-9
  2. NIAID. National Institute of Allergy and Infectious Diseases (2001) Garlic supplements can impede HIV medication. http://www.niaid.nih.gov/newsroom/releases/garlic.htm
  3. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J (2002) "The Effect of Garlic Supplements on the Pharmacokinetics of Saquinavir." Clin Infect Dis, 34, p. 234-238
  4. Borek C (2002) "Garlic supplements and saquinavir." Clin Infect Dis, 35, p. 343
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

amprenavir food

Applies to: amprenavir

GENERALLY AVOID: Administration with a high-fat meal may decrease the oral bioavailability of amprenavir. The mechanism is unknown. In healthy volunteers, consumption of a standardized high-fat meal decreased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of amprenavir (1200 mg single oral dose) by 36% and 21%, respectively, compared to administration in the fasted state. The time to reach Cmax (Tmax) was increased 44% following a high-fat meal.

Grapefruit juice does not appear to significantly affect the pharmacokinetics of amprenavir. In 12 healthy volunteers, administration with grapefruit juice (200 mL) decreased the mean peak plasma concentration (Cmax) of amprenavir (1200 mg single oral dose) by 22% compared to water. The median time to reach Cmax (Tmax) was prolonged from 0.75 to 1.13 hours. These pharmacokinetic changes are not thought to be clinically significant, since antiretroviral response is more closely associated with systemic exposure (AUC) and trough plasma concentration (Cmin), which were not affected in the study.

MANAGEMENT: Amprenavir may be taken with or without food, but should not be taken with a high-fat meal.

References

  1. (2001) "Product Information. Agenerase (amprenavir)." Glaxo Wellcome
  2. Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM (2002) "Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice." Antimicrob Agents Chemother, 46, p. 1589-1590

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.